SG Americas Securities
APLS

SG Americas Securities’s Apellis Pharmaceuticals APLS Stock Holding History

SG Americas Securities’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29M Buy
+150,000
New +$3.23M ﹤0.01% 1602
2024
Q1 		– Sell
-145,000
Closed -$316K – 2955
2023
Q4 		$316K Buy
145,000
+131,500
+974% +$6.67M ﹤0.01% 1793
2023
Q3 		$2K Buy
+13,500
New +$593K ﹤0.01% 3079
2023
Q2 		– Sell
-300,000
Closed -$2.19M – 2274
2023
Q1 		$2.19M Buy
+300,000
New +$17.3M 0.03% 613

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SG Americas Securities's APLS Position: Q1 2026 in Review

SG Americas Securities reduced its Apellis Pharmaceuticals (APLS) stake by 95% in Q1 2026, selling an estimated $11.6M and leaving 29,601 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

SG Americas Securities first reported a position in APLS in Q1 2019 and has held it in 28 quarters since. The position peaked at $14.2M in Q4 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • SG Americas Securities held 29,601 shares of Apellis Pharmaceuticals worth $1.19M as of Q1 2026.
  • SG Americas Securities sold 537,445 Apellis Pharmaceuticals shares in Q1 2026, an estimated $11.6M.
  • Apellis Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #1653 holding.
  • SG Americas Securities first reported a position in Apellis Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • SG Americas Securities's Apellis Pharmaceuticals position peaked at $14.2M in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.